<article article-type="case-study" dtd-version="1.4" id="jpr370093" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JPGN Rep</journal-id><journal-id journal-id-type="iso-abbrev">JPGN Rep</journal-id><journal-id journal-id-type="pmc-domain-id">4376</journal-id><journal-id journal-id-type="pmc-domain">jpgnreps</journal-id><journal-id journal-id-type="publisher-id">JPR3</journal-id><journal-title-group><journal-title>JPGN Reports</journal-title></journal-title-group><issn pub-type="epub">2691-171X</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12894054</article-id><article-id pub-id-type="pmcid-ver">PMC12894054.1</article-id><article-id pub-id-type="pmcaid">12894054</article-id><article-id pub-id-type="pmcaiid">12894054</article-id><article-id pub-id-type="pmid">41695048</article-id><article-id pub-id-type="doi">10.1002/jpr3.70093</article-id><article-id pub-id-type="publisher-id">JPR370093</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="heading"><subject>Hepatology</subject></subj-group></subj-group></article-categories><title-group><article-title>A case of autoimmune hepatitis in a patient with inflammatory bowel disease and significant lymphadenopathy in the porta hepatis</article-title><alt-title alt-title-type="left-running-head">MALAMET <sc>et al.</sc>
</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="jpr370093-cr-0001"><name name-style="western"><surname>Malamet</surname><given-names initials="BJ">Benjamin J.</given-names></name><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-2266-3636</contrib-id><xref ref-type="aff" rid="jpr370093-aff-0001">
<sup>1</sup>
</xref><address><email>benmalamet@gmail.com</email></address></contrib><contrib contrib-type="author" id="jpr370093-cr-0002"><name name-style="western"><surname>Joerger</surname><given-names initials="S">Shannon</given-names></name><xref ref-type="aff" rid="jpr370093-aff-0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" id="jpr370093-cr-0003"><name name-style="western"><surname>Caudill</surname><given-names initials="K">Karen</given-names></name><xref ref-type="aff" rid="jpr370093-aff-0002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" id="jpr370093-cr-0004"><name name-style="western"><surname>He</surname><given-names initials="M">Mai</given-names></name><xref ref-type="aff" rid="jpr370093-aff-0003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" id="jpr370093-cr-0005"><name name-style="western"><surname>Genere</surname><given-names initials="JR">Juan Reyes</given-names></name><xref ref-type="aff" rid="jpr370093-aff-0004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" id="jpr370093-cr-0006"><name name-style="western"><surname>Stoll</surname><given-names initials="J">Janis</given-names></name><xref ref-type="aff" rid="jpr370093-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jpr370093-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition</named-content>
<institution>Washington University in St. Louis School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="jpr370093-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Radiology</named-content>
<institution>Washington University in St. Louis School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="jpr370093-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Pathology and Immunology</named-content>
<institution>Washington University in St. Louis School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><aff id="jpr370093-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine, Division of Gastroenterology</named-content>
<institution>Washington University in St. Louis School of Medicine</institution>
<city>St. Louis</city>
<named-content content-type="country-part">Missouri</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold> Benjamin J. Malamet, Department of Pediatrics, MSC 8116‐43‐9, 660 S. Euclid Ave, St. Louis, MO 63110, USA.<break/>
Email: <email>benmalamet@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2026</year></pub-date><volume>7</volume><issue seq="30">1</issue><issue-id pub-id-type="pmc-issue-id">507520</issue-id><issue-id pub-id-type="doi">10.1002/jpr3.v7.1</issue-id><fpage>6</fpage><lpage>10</lpage><history><date date-type="rev-recd"><day>23</day><month>8</month><year>2025</year></date><date date-type="received"><day>05</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>08</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-16 15:25:13.347"><day>16</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2025 The Author(s). <italic toggle="yes">JPGN Reports</italic> published by Wiley Periodicals LLC on behalf of The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.</copyright-statement><license><ali:license_ref content-type="ccbynclicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="JPR3-7-6.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri content-type="pdf" xlink:href="file:JPR3-7-6.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>Abstract</title><p>The diagnosis of autoimmune hepatitis (AIH) is supported by the presence of elevated transaminases, hypergammaglobulinemia, liver biopsy consistent with AIH, and the presence of AIH autoantibodies. In this case presentation, we highlight the challenges associated with diagnosing AIH in a patient with inflammatory bowel disease (IBD) who presented with elevated transaminases, hypergammaglobulinemia, and without typical autoantibodies. Additionally, on hepatic ultrasound, the patient was found to have hepatic lymphadenopathy concerning for infection or malignancy. Furthermore, the patient's IBD was treated with vedolizumab, which is associated with drug‐induced liver injury. They were previously treated with azathioprine, which is associated with malignancy. Ultimately, a liver biopsy was able to confirm the diagnosis of AIH after all other potential causes of elevated transaminases were excluded.</p></abstract><kwd-group><kwd id="jpr370093-kwd-0001">endoscopic ultrasound</kwd><kwd id="jpr370093-kwd-0002">gastroenterology</kwd><kwd id="jpr370093-kwd-0003">hepatology</kwd><kwd id="jpr370093-kwd-0004">pediatrics</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>
<institution-wrap><institution>None</institution></institution-wrap>
</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="5"/><word-count count="2242"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:11.02.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation id="jpr370093-cit-0009" publication-type="journal">
<string-name name-style="western">
<surname>Malamet</surname>
<given-names>BJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Joerger</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Caudill</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>He</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Genere</surname>
<given-names>JR</given-names>
</string-name>, <string-name name-style="western">
<surname>Stoll</surname>
<given-names>J</given-names>
</string-name>. <article-title>A case of autoimmune hepatitis in a patient with inflammatory bowel disease and significant lymphadenopathy in the porta hepatis</article-title>. <source>JPGN Rep</source>. <year>2026</year>;<volume>7</volume>:<fpage>6</fpage>‐<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1002/jpr3.70093</pub-id>
</mixed-citation>
</p></notes></front><body><sec id="jpr370093-sec-0010"><label>1</label><title>INTRODUCTION</title><p>The diagnosis of autoimmune hepatitis (AIH) is supported by the presence of elevated transaminases, hypergammaglobulinemia, liver biopsy consistent with AIH, and the presence of AIH autoantibodies, including antinuclear antibodies (ANA), smooth muscle antibodies (SMA), anti‐liver kidney microsomal type‐1 antibodies (anti‐LKM‐1) and/or anti‐liver cytosol type 1 antibody (anti‐LC‐1).<xref ref-type="bibr" rid="jpr370093-bib-0001">
<sup>1</sup>
</xref> Inflammatory bowel disease (IBD) is an umbrella term to describe disorders of chronic gastrointestinal tract inflammation, further subclassified as Crohn's disease, ulcerative colitis, and indeterminate colitis. Hepatobiliary disorders affect 20%–30% of patients with IBD.<xref ref-type="bibr" rid="jpr370093-bib-0002">
<sup>2</sup>
</xref> Vedolizumab is associated with drug‐induced liver injury, and azathioprine is associated with malignancy.<xref ref-type="bibr" rid="jpr370093-bib-0003">
<sup>3</sup>
</xref>, <xref ref-type="bibr" rid="jpr370093-bib-0004">
<sup>4</sup>
</xref> We highlight the challenge of arriving at the diagnosis of AIH in a 16‐year‐old female with inflammatory bowel disease who presented with elevated transaminases, direct hyperbilirubinemia, and significant lymphadenopathy in the porta‐hepatis.</p></sec><sec id="jpr370093-sec-0020"><label>2</label><title>CASE REPORT</title><p>The patient was a 16‐year‐old female with a history of indeterminate colitis (in clinical and biochemical remission), migraines, and epilepsy, who presented to the hospital for elevated transaminases and direct hyperbilirubinemia discovered on routine laboratory testing (Table <xref ref-type="table" rid="jpr370093-tbl-0001">1</xref>). She received vedolizumab (every 5 weeks) for treatment of IBD, and was previously treated with mesalamine, azathioprine, and infliximab. On hospital admission, she reported 1 week of nausea, vomiting, anorexia, diarrhea, headache, increased fatigue, confusion, and slowed speech. She had a significant family history of a grandmother with AIH. Laboratory testing demonstrated leukocytosis, direct hyperbilirubinemia, and mildly elevated coagulation studies (Table <xref ref-type="table" rid="jpr370093-tbl-0001">1</xref>). Her physical exam findings included mild scleral icterus and no hepatosplenomegaly, lymphadenopathy, asterixis, or bruising. A liver ultrasound was ordered and revealed a thick‐walled gallbladder with surrounding edema and markedly enlarged lymph nodes in the porta‐hepatis.</p><table-wrap content-type="Table" id="jpr370093-tbl-0001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patient's lab values at presentation, readmission, and 8 months after presentation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000"/><col align="left" span="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000"/><col align="left" span="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000"/><col align="left" span="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000"/><col align="left" span="1" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" colspan="1" rowspan="1" valign="bottom">Lab (units)</th><th align="left" colspan="1" rowspan="1" valign="bottom">Value at presentation</th><th align="left" colspan="1" rowspan="1" valign="bottom">Value at readmission</th><th align="left" colspan="1" rowspan="1" valign="bottom">Value at 8 months after presentation</th><th align="left" colspan="1" rowspan="1" valign="bottom">Normal value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1" valign="top">WBC (K/cumm)</td><td align="left" colspan="1" rowspan="1" valign="top">12</td><td align="left" colspan="1" rowspan="1" valign="top">15.3</td><td align="left" colspan="1" rowspan="1" valign="top">10.1</td><td align="left" colspan="1" rowspan="1" valign="top">3.8–9.9</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Hgb (g/dL)</td><td align="left" colspan="1" rowspan="1" valign="top">13</td><td align="left" colspan="1" rowspan="1" valign="top">12.1</td><td align="left" colspan="1" rowspan="1" valign="top">13.4</td><td align="left" colspan="1" rowspan="1" valign="top">5.5–11.9</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Hct (%)</td><td align="left" colspan="1" rowspan="1" valign="top">37.9</td><td align="left" colspan="1" rowspan="1" valign="top">35.4</td><td align="left" colspan="1" rowspan="1" valign="top">38.9</td><td align="left" colspan="1" rowspan="1" valign="top">35.6–45.5</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Plt (K/cumm)</td><td align="left" colspan="1" rowspan="1" valign="top">244</td><td align="left" colspan="1" rowspan="1" valign="top">293</td><td align="left" colspan="1" rowspan="1" valign="top">394</td><td align="left" colspan="1" rowspan="1" valign="top">150–400</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Neutrophils abs (K/cumm)</td><td align="left" colspan="1" rowspan="1" valign="top">2.8</td><td align="left" colspan="1" rowspan="1" valign="top">3.2</td><td align="left" colspan="1" rowspan="1" valign="top">4.6</td><td align="left" colspan="1" rowspan="1" valign="top">1.7–6.5</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Lymphocytes abs (K/cumm)</td><td align="left" colspan="1" rowspan="1" valign="top">3.7</td><td align="left" colspan="1" rowspan="1" valign="top">5</td><td align="left" colspan="1" rowspan="1" valign="top">4.1</td><td align="left" colspan="1" rowspan="1" valign="top">0.8–3.3</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Monocytes abs (K/cumm)</td><td align="left" colspan="1" rowspan="1" valign="top">0.8</td><td align="left" colspan="1" rowspan="1" valign="top">0.6</td><td align="left" colspan="1" rowspan="1" valign="top">0.6</td><td align="left" colspan="1" rowspan="1" valign="top">0.2–0.8</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Eosinophils abs (K/cumm)</td><td align="left" colspan="1" rowspan="1" valign="top">5</td><td align="left" colspan="1" rowspan="1" valign="top">6.4</td><td align="left" colspan="1" rowspan="1" valign="top">0.6</td><td align="left" colspan="1" rowspan="1" valign="top">0.0–0.5</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Basophils (K/cumm)</td><td align="left" colspan="1" rowspan="1" valign="top">0.2</td><td align="left" colspan="1" rowspan="1" valign="top">0.3</td><td align="left" colspan="1" rowspan="1" valign="top">0</td><td align="left" colspan="1" rowspan="1" valign="top">0.0–0.1</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Total bilirubin (mg/dL)</td><td align="left" colspan="1" rowspan="1" valign="top">2.1</td><td align="left" colspan="1" rowspan="1" valign="top">3.9</td><td align="left" colspan="1" rowspan="1" valign="top">0.3</td><td align="left" colspan="1" rowspan="1" valign="top">0.1–1.2</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Direct bilirubin (mg/dL)</td><td align="left" colspan="1" rowspan="1" valign="top">1.4</td><td align="left" colspan="1" rowspan="1" valign="top">2.6</td><td align="left" colspan="1" rowspan="1" valign="top">0.1</td><td align="left" colspan="1" rowspan="1" valign="top">0.1–0.3</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Protein (g/dL)</td><td align="left" colspan="1" rowspan="1" valign="top">7.9</td><td align="left" colspan="1" rowspan="1" valign="top">8.8</td><td align="left" colspan="1" rowspan="1" valign="top">6.8</td><td align="left" colspan="1" rowspan="1" valign="top">6.5–8.5</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Albumin (g/dL)</td><td align="left" colspan="1" rowspan="1" valign="top">3.2</td><td align="left" colspan="1" rowspan="1" valign="top">3.5</td><td align="left" colspan="1" rowspan="1" valign="top">4</td><td align="left" colspan="1" rowspan="1" valign="top">3.2–5.0</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">ALP (Units/L)</td><td align="left" colspan="1" rowspan="1" valign="top">156</td><td align="left" colspan="1" rowspan="1" valign="top">219</td><td align="left" colspan="1" rowspan="1" valign="top">65</td><td align="left" colspan="1" rowspan="1" valign="top">70–260</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">ALT (Units/L)</td><td align="left" colspan="1" rowspan="1" valign="top">494</td><td align="left" colspan="1" rowspan="1" valign="top">873</td><td align="left" colspan="1" rowspan="1" valign="top">11</td><td align="left" colspan="1" rowspan="1" valign="top">7–45</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">AST (Units/L)</td><td align="left" colspan="1" rowspan="1" valign="top">338</td><td align="left" colspan="1" rowspan="1" valign="top">706</td><td align="left" colspan="1" rowspan="1" valign="top">18</td><td align="left" colspan="1" rowspan="1" valign="top">10–50</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">GGT (Units/L)</td><td align="left" colspan="1" rowspan="1" valign="top">48</td><td align="left" colspan="1" rowspan="1" valign="top">48</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">5–35</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">PT (seconds)</td><td align="left" colspan="1" rowspan="1" valign="top">14.7</td><td align="left" colspan="1" rowspan="1" valign="top">15</td><td align="left" colspan="1" rowspan="1" valign="top">11.9</td><td align="left" colspan="1" rowspan="1" valign="top">9–14</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">INR</td><td align="left" colspan="1" rowspan="1" valign="top">1.3</td><td align="left" colspan="1" rowspan="1" valign="top">1.4</td><td align="left" colspan="1" rowspan="1" valign="top">1.04</td><td align="left" colspan="1" rowspan="1" valign="top">0.8–1.2</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">PTT (seconds)</td><td align="left" colspan="1" rowspan="1" valign="top">42</td><td align="left" colspan="1" rowspan="1" valign="top">39</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">27–37</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">IgG (mg/dL)</td><td align="left" colspan="1" rowspan="1" valign="top">2556</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">1230</td><td align="left" colspan="1" rowspan="1" valign="top">700–1600</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">ANA</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Liver/kidney microsome type 1 antibody</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Smooth muscle antibody</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">EBV nuclear antibody</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">EBV VCA IgG</td><td align="left" colspan="1" rowspan="1" valign="top">Positive</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">EBV VCA IgM</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">CMV IgG</td><td align="left" colspan="1" rowspan="1" valign="top">Positive</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">CMV IgM</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">CMV DNA PCR</td><td align="left" colspan="1" rowspan="1" valign="top">Not Detected</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Not detected</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Adenovirus PCR blood</td><td align="left" colspan="1" rowspan="1" valign="top">Not Detected</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Not detected</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Enterovirus PCR blood</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Hepatitis A IgM</td><td align="left" colspan="1" rowspan="1" valign="top">Nonreactive</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Hepatitis B core IgM</td><td align="left" colspan="1" rowspan="1" valign="top">Nonreactive</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Hepatitis C antibody</td><td align="left" colspan="1" rowspan="1" valign="top">Nonreactive</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Nonreactive</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Respiratory pathogen panel</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Ceruloplasmin (mg/dL)</td><td align="left" colspan="1" rowspan="1" valign="top">35.4</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">16–45</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Cryptococcal antigen, serum blood</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Toxoplasma IgG</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Toxoplasma IgM</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Histoplasma antigen urine (mg/mL)</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Bartonella antibody panel</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Blastomyces antibody</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top">Histoplasma antibody Blood</td><td align="left" colspan="1" rowspan="1" valign="top">Negative</td><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Negative</td></tr></tbody></table><table-wrap-foot><fn id="jpr370093-tbl1-note-0001"><p>Abbreviations: ABS, absolute; ALP, alkaline phosphatase; ALT, alanine transaminase; ANA, antinuclear antibody; AST, aspartate aminotransferase; CMV, cytomegalovirus; EBV, Epstein‐Barr Virus; GGT, gamma‐glutamyl transferase; Hct, hematocrit; Hgb, hemoglobin; Ig, immunoglobulin; INR, international normalized ratio; PCR, polymerase chain reaction; Plt, platelets; PT, prothrombin time; PTT, partial thromboplastin time; VCA, viral capsid antigen; WBC, white blood cell count.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Differential diagnoses included AIH, Wilson's disease, infection, malignancy, drug‐induced liver injury, and primary sclerosing cholangitis. Immunoglobulin G (IgG) levels were elevated. ANA, SMA, and anti‐LKM‐1 antibodies were negative, but anti‐LC‐1 was not collected. Ceruloplasmin level was normal. Magnetic resonance cholangiopancreatography (MRCP) showed mild periportal edema without biliary ductal dilation, pericholecystic edema, gallbladder wall thickening without evidence of cholelithiasis, and enlarged porta‐hepatis lymph nodes. The largest node measured 3.1 × 2.7 cm (Figure <xref ref-type="fig" rid="jpr370093-fig-0001">1</xref>). The infectious disease team was consulted to exclude infectious causes of hepatitis, and testing (Table <xref ref-type="table" rid="jpr370093-tbl-0001">1</xref>) was negative for acute viral hepatitis, endemic mycotic infections, and infections related to exposure to family cats (<italic toggle="yes">Toxoplasma</italic> and <italic toggle="yes">Bartonella)</italic>. Epstein‐Barr virus and cytomegalovirus antibodies were consistent with past infection. After 3 days, she clinically improved with resolving transaminases and was discharged with close outpatient follow‐up to coordinate additional testing.</p><fig fig-type="Figure" id="jpr370093-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Magnetic resonance cholangiopancreatography demonstrating enlarged porta‐hepatis lymph nodes, the largest of which (*) measures 3.12 × 2.7 cm and 1.6 × 2.7 cm. Mild periportal edema without biliary ductal dilation is seen in addition to severe pericholecystic edema and gallbladder wall thickening without evidence of cholelithiasis.</p></caption><graphic id="jats-graphic-1" orientation="portrait" position="anchor" xlink:href="JPR3-7-6-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>The patient was readmitted 5 days later when follow‐up laboratory testing revealed increased transaminases and total and direct bilirubin (Table <xref ref-type="table" rid="jpr370093-tbl-0001">1</xref>). Since discharge, she noted worsening scleral icterus, anorexia, fatigue, difficulty concentrating, and new intermittent dull periumbilical pain. Her physical examination was significant for scleral icterus, cervical lymphadenopathy, and periumbilical and bilateral lower quadrant abdominal tenderness, with no evidence of hepatosplenomegaly, asterixis, or bruising.</p><p>Oncology was consulted to evaluate for malignancy. Uric acid level was normal (4 mg/dL), ref. range: 2.5–7.0 mg/dL), and lactate dehydrogenase was mildly elevated (327 Units/L), ref. range: 100–250 Units/L), but the specimen was hemolyzed. A positron emission tomography scan showed hypermetabolic lymph nodes above and below the diaphragm, the most hypermetabolic in the porta‐hepatis, consistent with reactive lymphadenopathy in the setting of autoimmune disease, low‐grade hematologic malignancy, or infectious process. Tissue analysis was required to facilitate a diagnosis and endoscopic ultrasound‐guided fine needle biopsy was pursued to permit a same‐session biopsy of the porta‐hepatis lymph nodes and liver. An advanced endoscopist from our adult gastroenterology divison performed the procedure. Lymph node biopsy demonstrated no clonal or significant B‐cell or aberrant T‐cell populations and normal flow cytometry analysis. Lymph node aerobic/anaerobic culture, fungal culture, mycobacterial culture, <italic toggle="yes">Toxoplasma</italic> polymerase chain reaction (PCR), and <italic toggle="yes">Bartonella</italic> PCR were negative. Liver biopsy was consistent with autoimmune hepatitis, showing portal inflammation with mixed lymphocytic inflammation, plasma cell clusters (&gt;5 plasma cells per cluster), eosinophilia, and mild interface activity, along with lobulitis and lymphoplasmacytosis (Figure <xref ref-type="fig" rid="jpr370093-fig-0002">2</xref>).<xref ref-type="bibr" rid="jpr370093-bib-0005">
<sup>5</sup>
</xref>
</p><fig fig-type="Figure" id="jpr370093-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Liver core biopsy demonstrating portal inflammation with mixed lymphocytic inflammation, plasma cell clusters, eosinophilia, and mild interface activity, along with lobulitis and lymphoplasmacytosis consistent with autoimmune hepatitis, 200X, hematoxylin and eosin stain. The right‐upper corner inlay demonstrates plasma cell clusters, 400X, hematoxylin and eosin stain.</p></caption><graphic id="jats-graphic-3" orientation="portrait" position="anchor" xlink:href="JPR3-7-6-g002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Treatment for AIH was started with 60 mg of intravenous methylprednisolone. Transaminases improved (aspartate aminotransferase 458, alanine transaminase 639), and the patient was discharged on 60 mg of prednisone daily, 250 mg of ursodeoxycholic acid daily, and 30 mg of lansoprazole daily.</p><p>In outpatient follow‐up, prednisone was weaned as laboratory studies improved. The patient was started on azathioprine but developed nausea and vomiting. Subsequently, she was started on 180 mg of mycophenolate twice daily. Vedolizumab was continued. At her 8‐month follow‐up, laboratory testing improved (Table <xref ref-type="table" rid="jpr370093-tbl-0001">1</xref>), and she was weaned to 2.5 mg of prednisone daily and continued on mycophenolate and ursodeoxycholic acid daily. Repeat MRCP 8 months after initial presentation was normal.</p></sec><sec id="jpr370093-sec-0030" sec-type="discussion"><label>3</label><title>DISCUSSION</title><p>This case demonstrates a unique presentation of AIH in a patient without positive autoantibodies and hepatic lymphadenopathy concerning for infection or malignancy, while also on an immunosuppressive drug associated with drug‐induced liver injury.</p><p>At the onset of AIH, autoantibodies may be negative and later become detectable in follow‐up.<xref ref-type="bibr" rid="jpr370093-bib-0001">
<sup>1</sup>
</xref> In this case, ANA, SMA, and anti‐LKM‐1 were negative at presentation, and anti‐LC‐1 was not collected. Thus, the diagnosis of AIH depended on ruling out other causes of elevated transaminases and lymphadenopathy and collecting a lymph node and liver biopsy. To that end, an endoscopic ultrasound guided fine needle biopsy provided critical information needed in this case. This approach permits luminal and hepatobiliary evaluation of the foregut in the same session. The other added advantage is that this procedure is performed under anesthesia and is not painful. PET scan obtained before the procedure allowed us to determine that the most hypermetabolic nodes were in the porta‐hepatis, and no additional lymph nodes needed to be biopsied while under anesthesia. Although lymphadenopathy in the porta‐hepatis can be associated with AIH,<xref ref-type="bibr" rid="jpr370093-bib-0006">
<sup>6</sup>
</xref> the degree of lymphadenopathy in this patient raised additional concern for a malignancy. Thus, a lymph node biopsy was collected as it could be obtained simultaneously with the liver biopsy. Thiopurine use is associated with lymphoma.<xref ref-type="bibr" rid="jpr370093-bib-0004">
<sup>4</sup>
</xref> However, this is unlikely, given remote use, and biopsy excluded malignancy. Infectious testing was completed with special attention to <italic toggle="yes">Bartonella</italic> and <italic toggle="yes">Toxoplasma</italic> infection given cat exposure, and opportunistic infection given the patient's immunosuppression. Endemic mycosis was also ruled out, specifically histoplasmosis, which can present with lymphadenopathy and elevated transaminases.<xref ref-type="bibr" rid="jpr370093-bib-0007">
<sup>7</sup>
</xref> When comparing this patient to other IBD patients, in clinical trials of vedolizumab there were relatively low rates of serious infections and improved safety compared to adalimumab,<xref ref-type="bibr" rid="jpr370093-bib-0008">
<sup>8</sup>
</xref> another common biologic for the treatment of IBD. Drug‐induced liver injury has been described in IBD patients taking vedolizumab. These patients also presented with elevated transaminases and bilirubin, the majority in a cholestatic pattern; however, in patients described in the literature, effects were seen within the first six doses of vedolizumab, while our patient had been on vedolizumab for more than 2 years.<xref ref-type="bibr" rid="jpr370093-bib-0003">
<sup>3</sup>
</xref> IBD providers should be aware of the high rates of hepatobiliary disorders in IBD patients, which can be due to primary hepatic disorders or drug‐induced liver injury related to IBD treatments.<xref ref-type="bibr" rid="jpr370093-bib-0002">
<sup>2</sup>
</xref> Ultimately, a liver biopsy was obtained and revealed the definitive diagnosis of AIH in the patient.</p></sec><sec id="jpr370093-sec-0040" sec-type="conclusions"><label>4</label><title>CONCLUSION</title><p>Through this case, we demonstrate the challenge of diagnosing AIH in a 16‐year‐old female with IBD who presented with elevated transaminases, direct hyperbilirubinemia, and significant lymphadenopathy in the porta‐hepatis, concerning for infection or malignancy. Patients with IBD are at high risk for hepatobiliary disorders, and furthermore, our patient was taking vedolizumab, which is associated with drug‐induced liver injury. Uniquely in our case, endoscopic ultrasound guided fine needle biopsy of porta hepatis lymph nodes and liver allowed us to evaluate for malignancy and diagnose AIH during the same procedure.</p></sec><sec id="jpr370093-sec-0060" sec-type="COI-statement"><title>CONFLICT OF INTEREST STATEMENT</title><p>Juan Reyes Genere, MD: Boston Scientific, Consultant. Edulis Therapeutics, Consultant/Co‐Founder.</p></sec><sec id="jpr370093-sec-0070"><title>ETHICS STATEMENT</title><p>The patient's mother provided consent to publish this case report.</p></sec></body><back><ack id="jpr370093-sec-0050"><title>ACKNOWLEDGMENTS</title><p>The authors have no funding to report.</p></ack><ref-list content-type="cited-references" id="jpr370093-bibl-0001"><title>REFERENCES</title><ref id="jpr370093-bib-0001"><label>1</label><mixed-citation id="jpr370093-cit-0001" publication-type="journal">
<string-name name-style="western">
<surname>Mieli‐Vergani</surname>
<given-names>G</given-names>
</string-name>, <string-name name-style="western">
<surname>Vergani</surname>
<given-names>D</given-names>
</string-name>, <string-name name-style="western">
<surname>Baumann</surname>
<given-names>U</given-names>
</string-name>, et al. <article-title>Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2018</year>;<volume>66</volume>(<issue>2</issue>):<fpage>345</fpage>‐<lpage>360</lpage>.<pub-id pub-id-type="pmid">29356770</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MPG.0000000000001801</pub-id></mixed-citation></ref><ref id="jpr370093-bib-0002"><label>2</label><mixed-citation id="jpr370093-cit-0002" publication-type="journal">
<string-name name-style="western">
<surname>Saubermann</surname>
<given-names>LJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Deneau</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Falcone</surname>
<given-names>RA</given-names>
</string-name>, et al. <article-title>Hepatic issues and complications associated with inflammatory bowel disease</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2017</year>;<volume>64</volume>(<issue>4</issue>):<fpage>639</fpage>‐<lpage>652</lpage>.<pub-id pub-id-type="pmid">27984347</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/MPG.0000000000001492</pub-id></mixed-citation></ref><ref id="jpr370093-bib-0003"><label>3</label><mixed-citation id="jpr370093-cit-0003" publication-type="journal">
<string-name name-style="western">
<surname>Honap</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Sticova</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western">
<surname>Theocharidou</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Vedolizumab‐associated drug‐induced liver injury: a case series</article-title>. <source>Inflamm Bowel Dis</source>. <year>2021</year>;<volume>27</volume>(<issue>3</issue>):<fpage>e32</fpage>‐<lpage>e34</lpage>.<pub-id pub-id-type="pmid">33155638</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/ibd/izaa286</pub-id></mixed-citation></ref><ref id="jpr370093-bib-0004"><label>4</label><mixed-citation id="jpr370093-cit-0004" publication-type="journal">
<string-name name-style="western">
<surname>Faye</surname>
<given-names>AS</given-names>
</string-name>, <string-name name-style="western">
<surname>Holmer</surname>
<given-names>AK</given-names>
</string-name>, <string-name name-style="western">
<surname>Axelrad</surname>
<given-names>JE</given-names>
</string-name>. <article-title>Cancer in inflammatory bowel disease</article-title>. <source>Gastroenterol Clin North Am</source>. <year>2022</year>;<volume>51</volume>(<issue>3</issue>):<fpage>649</fpage>‐<lpage>666</lpage>.<pub-id pub-id-type="pmid">36153115</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.gtc.2022.05.003</pub-id></mixed-citation></ref><ref id="jpr370093-bib-0005"><label>5</label><mixed-citation id="jpr370093-cit-0005" publication-type="journal">
<string-name name-style="western">
<surname>Lohse</surname>
<given-names>AW</given-names>
</string-name>, <string-name name-style="western">
<surname>Sebode</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Bhathal</surname>
<given-names>PS</given-names>
</string-name>, et al. <article-title>Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH pathology group</article-title>. <source>Liver Int</source>. <year>2022</year>;<volume>42</volume>(<issue>5</issue>):<fpage>1058</fpage>‐<lpage>1069</lpage>.<pub-id pub-id-type="pmid">35230735</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.15217</pub-id></mixed-citation></ref><ref id="jpr370093-bib-0006"><label>6</label><mixed-citation id="jpr370093-cit-0006" publication-type="journal">
<string-name name-style="western">
<surname>Malik</surname>
<given-names>N</given-names>
</string-name>, <string-name name-style="western">
<surname>Venkatesh</surname>
<given-names>SK</given-names>
</string-name>. <article-title>Imaging of autoimmune hepatitis and overlap syndromes</article-title>. <source>Abdominal Radiology</source>. <year>2017</year>;<volume>42</volume>(<issue>1</issue>):<fpage>19</fpage>‐<lpage>27</lpage>.<pub-id pub-id-type="pmid">27999888</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00261-016-1019-x</pub-id></mixed-citation></ref><ref id="jpr370093-bib-0007"><label>7</label><mixed-citation id="jpr370093-cit-0007" publication-type="journal">
<string-name name-style="western">
<surname>Araúz</surname>
<given-names>AB</given-names>
</string-name>, <string-name name-style="western">
<surname>Papineni</surname>
<given-names>P</given-names>
</string-name>. <article-title>Histoplasmosis</article-title>. <source>Infect Dis Clin North Am</source>. <year>2021</year>;<volume>35</volume>(<issue>2</issue>):<fpage>471</fpage>‐<lpage>491</lpage>.<pub-id pub-id-type="pmid">34016287</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.idc.2021.03.011</pub-id></mixed-citation></ref><ref id="jpr370093-bib-0008"><label>8</label><mixed-citation id="jpr370093-cit-0008" publication-type="journal">
<string-name name-style="western">
<surname>Loftus</surname>
<given-names>EV</given-names>
</string-name>, <string-name name-style="western">
<surname>Feagan</surname>
<given-names>BG</given-names>
</string-name>, <string-name name-style="western">
<surname>Panaccione</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Long‐term safety of vedolizumab for inflammatory bowel disease</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2020</year>;<volume>52</volume>(<issue>8</issue>):<fpage>1353</fpage>‐<lpage>1365</lpage>.<pub-id pub-id-type="pmid">32876349</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/apt.16060</pub-id><pub-id pub-id-type="pmcid">PMC7540482</pub-id></mixed-citation></ref></ref-list></back></article>